Breaking Six College Football Coaches Face Mounting Pressure Ahead of 2026 Season Historic Wildfires Ravage France and Spain Amid Heat Waves, Triggering Mass Evacuations Iran Sets Six Demands for Strait of Hormuz Reopening New Documentary “Louder Than Fear” Delves into Travis Barker’s Life and Recovery Powerful 7.4 Magnitude Earthquake Strikes Western Colombia, Ecuador

Monday August 10, 2026

Reporter

Ascletis Pharma Inc.

2Articles Published

4Communities Covered

Published Articles

Press Release

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

6 hours ago

Press Release

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Aug 3